Ketazocine

This classification denotes an opioid receptor agonist with the molecular formula C18H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6IO4IG518S, chemically known as 2,6-methano-3-benzazocin-1(2h)-one, 3-(cyclopropylmethyl)-3,4,5,6-tetrahydro-8-hydroxy-6,11-dimethyl-, (2alpha,6alpha,11s*)- but generally known as ketazocine, which bears US NIH Compound Identifier 71426. European Medicines Agency schedules Ketazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08367MIG. The term KETAZOCINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 30, No. 10 1976, List 16). KETAZOCINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule ketazocine under HS 29333999 and SITC 51574. As of Q4 2014, KETAZOCINE remains the US FDA Preferred Term for this commodity. Ketazocine bears US NLM identifiers UMLS ID C0064303 and NCI Concept Code C83853. SMILES: O=C1C2N(CC3CC3)CCC(C2C)(C2C1CCC(O)C2)C.